ACETO Corporation (Nasdaq:ACET), an international company engaged
in the development, marketing, sale and distribution of Human
Health products, Pharmaceutical Ingredients and Performance
Chemicals, announced today financial results for the third quarter
of fiscal 2017 ended March 31, 2017.
Third Quarter Fiscal 2017 versus Third
Quarter Fiscal 2016
- Net sales of $190.1 million versus $157.9 million, a 20.4%
increase
- Gross profit of $42.3 million versus $38.3 million, a 10.5%
increase
- Net income of $5.6 million versus net income of $10.4 million,
a 46.4% decrease
- Diluted EPS of $0.16 versus $0.35, a 54.3% decrease
- Non-GAAP Adjusted Net Income of $13.6 million versus $12.5
million, a 8.7% increase
- Non-GAAP Adjusted EPS of $0.39 versus $0.42, a 7.1%
decrease
Management Commentary
“The third quarter represents our first
operating quarter with full inclusion of the recently-acquired
Citron and Lucid products. The expansion of our product
portfolio also brought us one step further along in our strategic
transition towards human health with our human health and pharma
ingredients business segments collectively accounting for over 75%
of total sales for the first time ever,” said Sal Guccione, Chief
Executive Officer of ACETO.
“Human Health sales and gross profit for the
quarter grew to $100 million and $25.7 million, respectively,
driven by the contribution of the Citron and Lucid
product sales. Consistent with the past two quarters,
increased competition in our generics business, particularly on one
generic product that began in the fourth quarter of fiscal 2016,
continued to impact year-over-year comparisons. Additionally,
lower sales and gross profit from more mature products were
partially offset by incremental sales and gross profit from new
products launched this fiscal year.
“During the quarter, we resolved the API supply
disruptions that had previously caused back orders on two Rising
products and we launched four Rising products for a total of nine
products year-to-date. We also launched two Citron products,” added
Mr. Guccione. “We continue to expect to launch three to six
additional Rising generic products during the fourth quarter. We
also expect to launch seven Citron products in the fourth quarter,
fewer than previously anticipated, for a total of 19 to 22 generic
product launches during fiscal 2017.”
“In part because of these launch delays and also
due to competitive pressures on our generics products portfolio, we
now expect fiscal year 2017 sales growth to be in the low-to-mid
teens percentage range and non-GAAP Adjusted EPS to be flat to 10%
below fiscal 2016, largely dependent upon the timing and
success of a particular anticipated new product launch. On a GAAP
basis, which reflects costs related to the strategic acquisition
and non-cash purchase accounting charges, EPS is expected to be
below last year by approximately 50% to 60%. Despite this
fiscal year’s operational challenges and difficult industry
conditions, we are encouraged by the progress we have made in
working through these challenges, and expect to see sequential
growth by the legacy Rising products in the fiscal fourth
quarter. Our resolve in returning to a steady annual growth
state is unwavering,” concluded Mr. Guccione.
Third Quarter Financial
Review
Net sales for the third quarter of fiscal 2017
were $190.1 million, an increase of 20.4% from $157.9 million
reported in the third quarter of fiscal 2016. Total Company gross
profit was $42.3 million, an increase of 10.5%, compared to $38.3
million in the third quarter of fiscal 2016. Gross margin for the
third quarter was 22.3% compared to 24.2% in the prior year
period.
Human Health segment sales were $99.8 million,
an increase of 69.8%, compared to $58.8 million for the third
quarter of fiscal 2016. The revenue increase was primarily due to
the acquisition of certain generic pharmaceutical products of
Citron and Lucid, from which sales of $52.2 million were included
in total segment sales, offsetting a sales decline at Rising of
$11.6 million. Nutritional product sales increased modestly in the
third quarter versus the prior year period. Gross profit for the
Human Health segment was $25.3 million, an increase of 32.3%,
compared to $19.1 million for the third quarter of fiscal 2016.
Gross margin for the third quarter was 25.3%, compared to 32.5% in
the prior year period. As with revenue, the increase in gross
profit was primarily due to the product acquisitions. The gross
margin decline was due to lower gross profitability of the acquired
Citron and Lucid products, which more than offset slight gross
margin improvements at both Rising and Nutritionals.
Pharmaceutical Ingredients segment sales were
$43.8 million, a decrease of 4.4%, compared to $45.8 million for
the third quarter of fiscal 2016. The segment’s sales decrease was
mainly due to lower volumes of intermediates sold abroad. Gross
profit in the quarter was $7.3 million, a 16.1% decrease compared
to $8.6 million for the third quarter of fiscal 2016. Gross margin
for the third quarter was 16.6%, compared to 18.9% in the prior
year period. The decrease in gross profit and margin was a result
of volume declines of both APIs and intermediates sold abroad, as
well as reduced sales of a certain API which typically yields a
higher gross margin.
Performance Chemicals segment sales were $46.5
million, a decrease of 12.8%, compared to $53.3 million for the
third quarter of fiscal 2016, due to lower domestic sales of
certain agriculture products, which more than offset higher sales
of specialty chemicals. Gross profit was $9.8 million, a decrease
of 7.2%, compared to $10.5 million for the third quarter of fiscal
2016. Gross margin was 21.0% for the third quarter, compared to
19.7% in the prior year period. The decrease in gross profit was
due to lower sales of agricultural protection products, while the
gross margin increase was due to a more profitable mix of these
products.
Total selling, general and administrative
expenses were $26.5 million compared to $19.5 million in the same
period last year, a 36.0% increase, with $5.4 million of the
increase attributable to the amortization expense associated with
the purchase of certain generic products and related assets of
Citron and Lucid and $1.7 million for Citron-related consulting
services. Research and Development expenses in the third quarter
totaled $2.6 million compared to $2.3 million in the prior year
period. The majority of R&D expenses are milestone based and
fluctuate quarterly.
Operating income in the third quarter of fiscal
2017 was $13.2 million, versus $16.5 million in the prior year’s
quarter. Net income was $5.6 million, or $0.16 per diluted share,
compared to net income of $10.4 million, or $0.35 per diluted
share, for the comparable quarter of fiscal 2016. Non-GAAP Adjusted
Net Income was $13.6 million in the third quarter, compared to
$12.5 million in the prior period, an 8.7% increase. Non-GAAP
Adjusted Earnings per Share were $0.39, compared to $0.42 in the
year ago third quarter, a 7.1% decrease.
Conference Call
Management will host a conference call to
discuss the operating and financial results at 9:00 a.m. ET on
Friday, May 5, 2017. To participate in the conference call,
please dial (877) 317-6789 or (412) 317-6789 approximately 10
minutes prior to the call. Please reference conference ID #
10105981.
The call is also being webcast with an
accompanying presentation, which can be accessed through the
investor relations section of the Company’s website,
www.aceto.com. Please access the website 15 minutes prior to
the start of the call to download and install any necessary audio
software and download the presentation.
A telephone replay of the conference call will
be available from 11:30 a.m. ET on May 5, 2017 until 11:59 p.m. ET
on May 9, 2017 and may be accessed by calling (888) 843-7419 and
referencing conference ID # 10105981. An archived replay of
the conference call will also be available in the investor
relations section of the Company’s website.
Use of Non-GAAP Financial
Information
In addition to U.S. GAAP results, this press
release also includes certain non-GAAP financial measures as
defined by the SEC. These measures, Adjusted Net Income and
Adjusted EPS, are based upon net income excluding amortization of
intangibles, debt extinguishment, amortization of debt discount,
debt issuance costs and deferred financing costs, transaction costs
and purchase accounting adjustments related to acquisitions. These
items should not be reviewed in isolation or considered substitutes
of the Company’s financial results as reported in accordance with
GAAP. Due to the nature of these items, it is important to
identify these items and to review them in conjunction with the
Company’s financial results reported in accordance with GAAP.
The exclusion of these items also allows investors to compare
results of operations in the current period to prior periods’
results based on the Company’s fundamental business performance and
analyze the operating trends of the business. The exclusion
of these items also allows management to evaluate the performance
of its business units.
Pursuant to the requirements of Regulation G,
reconciliations of Adjusted Net Income and Adjusted EPS to U.S.
GAAP net income and GAAP EPS are presented in the table Non-GAAP
Reconciliation of this press release.
About ACETO
ACETO Corporation, incorporated in 1947 and with
offices and operations in 10 countries, is engaged in the
development, marketing, sale and distribution of Human Health
products (finished dosage form generics and nutraceuticals),
Pharmaceutical Ingredients (pharmaceutical intermediates and active
pharmaceutical ingredients) and Performance Chemicals (specialty
chemicals and agricultural protection products).
FORWARD-LOOKING
STATEMENTS
This news release contains forward-looking
statements as that term is defined in the federal securities
laws. The events described in forward-looking statements
contained in this news release may not occur. Generally,
these statements relate to our business plans or strategies,
projected or anticipated benefits or other consequences of ACETO’s
plans or strategies, financing plans, projected or anticipated
benefits from acquisitions that ACETO may make, or a projection
involving anticipated revenues, earnings or other aspects of
ACETO’s operating results or financial position, and the outcome of
any contingencies. Any such forward-looking statements are
based on current expectations, estimates and projections of
management. ACETO intends for these forward-looking statements to
be covered by the safe-harbor provisions for forward-looking
statements. Words such as "may," "will," "expect," "believe,"
"anticipate," "project," "plan," "intend," "estimate," and
"continue," and their opposites and similar expressions are
intended to identify forward-looking statements. The
forward-looking statements contained in this press release include,
but are not limited to, the Company’s sales and earnings guidance
and statements regarding the expected impact of a recent
acquisition and product launches. ACETO cautions you
that these statements are not guarantees of future performance or
events and are subject to a number of uncertainties, risks and
other influences, many of which are beyond ACETO’s control, which
may influence the accuracy of the statements and the projections
upon which the statements are based. Factors that could
cause actual results to differ materially from those set forth or
implied by any forward-looking statement include, but are not
limited to, risks and uncertainties discussed in ACETO’s reports
filed with the Securities and Exchange Commission, including, but
not limited to, ACETO’s Annual Report on Form 10-K for the fiscal
year ended June 30, 2016 and other filings. Copies of these filings
are available at www.sec.gov.
Any one or more of these uncertainties, risks
and other influences could materially affect ACETO’s results of
operations and whether forward-looking statements made by ACETO
ultimately prove to be accurate. In addition, periodic
high-margin product sales may have a positive material financial
impact in a given quarter that may be non-recurring in future
quarters, thereby rendering one quarter's performance not useful as
a predictor of future quarters' results. ACETO’s actual
results, performance and achievements could differ materially from
those expressed or implied in these forward-looking
statements. ACETO undertakes no obligation to publicly
update or revise any forward-looking statements, whether from new
information, future events or otherwise.
(Financial Tables Follow)
|
|
|
|
Aceto Corporation and
Subsidiaries |
Consolidated Statements
of Income |
(in thousands, except per share
amounts) |
|
|
|
|
|
|
|
|
|
|
|
(unaudited) |
|
(unaudited) |
|
Three Months Ended |
|
Nine Months Ended |
|
March 31, |
|
March 31, |
|
|
2017 |
|
|
|
2016 |
|
|
|
2017 |
|
|
|
2016 |
|
Net sales |
|
$ |
190,128 |
|
|
$ |
157,926 |
|
|
$ |
443,698 |
|
|
$ |
423,100 |
|
Cost of sales |
|
|
147,809 |
|
|
|
119,637 |
|
|
|
339,735 |
|
|
|
314,362 |
|
Gross profit |
|
|
42,319 |
|
|
|
38,289 |
|
|
|
103,963 |
|
|
|
108,738 |
|
Gross profit % |
|
|
22.26 |
% |
|
|
24.24 |
% |
|
|
23.43 |
% |
|
|
25.70 |
% |
|
|
|
|
|
|
|
|
Selling, general
and |
|
|
|
|
|
|
|
|
administrative expenses |
|
|
26,519 |
|
|
|
19,498 |
|
|
|
75,614 |
|
|
|
56,377 |
|
Research and
development expenses |
|
|
2,607 |
|
|
|
2,319 |
|
|
|
4,998 |
|
|
|
6,280 |
|
Operating income |
|
|
13,193 |
|
|
|
16,472 |
|
|
|
23,351 |
|
|
|
46,081 |
|
|
|
|
|
|
|
|
|
Other expense, net of
interest expense |
|
|
(4,681 |
) |
|
|
(928 |
) |
|
|
(8,993 |
) |
|
|
(2,461 |
) |
|
|
|
|
|
|
|
|
Income before income
taxes |
|
|
|
8,512 |
|
|
|
15,544 |
|
|
|
14,358 |
|
|
|
43,620 |
|
Income tax
provision |
|
|
2,924 |
|
|
|
5,120 |
|
|
|
4,949 |
|
|
|
15,628 |
|
Net income |
|
$ |
5,588 |
|
|
$ |
10,424 |
|
|
$ |
9,409 |
|
|
$ |
27,992 |
|
|
|
|
|
|
|
|
|
Net income per common
share |
|
$ |
0.16 |
|
|
$ |
0.36 |
|
|
$ |
0.30 |
|
|
$ |
0.96 |
|
|
|
|
|
|
|
|
|
Diluted net income per
common share |
|
$ |
0.16 |
|
|
$ |
0.35 |
|
|
$ |
0.30 |
|
|
$ |
0.95 |
|
|
|
|
|
|
|
|
|
Weighted average shares
outstanding: |
|
|
|
|
|
|
|
|
Basic |
|
|
34,769 |
|
|
|
29,158 |
|
|
|
31,453 |
|
|
|
29,085 |
|
Diluted |
|
|
35,121 |
|
|
|
29,620 |
|
|
|
31,792 |
|
|
|
29,536 |
|
|
|
|
|
|
|
Aceto Corporation and
Subsidiaries |
|
Consolidated Balance Sheets |
|
(in thousands, except per-share
amounts) |
|
|
|
|
|
|
|
|
(unaudited) |
|
|
|
|
March 31, 2017 |
|
June 30, 2016 |
|
Assets |
|
|
|
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
|
|
Cash and
cash equivalents |
$ |
59,962 |
|
|
|
$ |
66,828 |
|
|
Investments |
|
1,966 |
|
|
|
|
881 |
|
|
Trade
receivables: less allowance for doubtful |
|
|
|
|
|
accounts:
March 31, 2017 $470; and June 30, 2016 $513 |
|
260,530 |
|
|
|
|
167,612 |
|
|
Other
receivables |
|
10,802 |
|
|
|
|
12,650 |
|
|
Inventory |
|
139,941 |
|
|
|
|
98,107 |
|
|
Prepaid
expenses and other current assets |
|
5,155 |
|
|
|
|
3,339 |
|
|
Deferred
income tax asset, net |
|
2,595 |
|
|
|
|
3,244 |
|
|
|
|
|
|
|
|
Total
current assets |
|
480,951 |
|
|
|
|
352,661 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment,
net |
|
10,289 |
|
|
|
|
10,044 |
|
|
Property held for
sale |
|
7,152 |
|
|
|
|
6,868 |
|
|
Goodwill |
|
241,741 |
|
|
|
|
67,871 |
|
|
Intangible assets,
net |
|
292,788 |
|
|
|
|
79,071 |
|
|
Deferred income tax
asset, net |
|
16,655 |
|
|
|
|
18,053 |
|
|
Other assets |
|
9,044 |
|
|
|
|
6,210 |
|
|
|
|
|
|
|
|
|
|
|
|
Total Assets |
$ |
1,058,620 |
|
|
|
$ |
540,778 |
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and
Shareholders' Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
|
|
|
|
Current
portion of long-term debt |
$ |
14,466 |
|
|
|
$ |
197 |
|
|
Accounts
payable |
|
111,364 |
|
|
|
|
46,034 |
|
|
Accrued
expenses |
|
106,243 |
|
|
|
|
52,675 |
|
|
Total
current liabilities |
|
232,073 |
|
|
|
|
98,906 |
|
|
|
|
|
|
|
|
Long-term debt,
net |
|
353,324 |
|
|
|
|
118,592 |
|
|
Long-term
liabilities |
|
60,302 |
|
|
|
|
6,344 |
|
|
Environmental
remediation liability |
|
3,008 |
|
|
|
|
3,352 |
|
|
Deferred income tax
liability |
|
7,762 |
|
|
|
|
9,142 |
|
|
Total
liabilities |
|
656,469 |
|
|
|
|
236,336 |
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and
contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders'
equity: |
|
|
|
|
|
|
|
|
|
Preferred
stock, 2,000 shares authorized; no shares issued and
outstanding |
|
- |
|
|
|
|
- |
|
|
Common
stock, $.01 par value: |
|
|
|
|
|
|
|
|
|
(75,000
shares authorized; 30,105 and 29,595 shares issued |
|
|
|
|
|
|
|
|
|
and
outstanding at March 31, 2017 and June 30, 2016, respectively) |
|
301 |
|
|
|
|
296 |
|
|
Capital
in excess of par value |
|
212,486 |
|
|
|
|
115,667 |
|
|
Retained
earnings |
|
198,139 |
|
|
|
|
194,804 |
|
|
Accumulated other comprehensive loss |
|
(8,775 |
) |
|
|
|
(6,325 |
) |
|
Total
shareholders' equity |
|
402,151 |
|
|
|
|
304,442 |
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and
shareholders' equity |
$ |
1,058,620 |
|
|
|
$ |
540,778 |
|
|
|
|
|
|
|
|
|
|
|
|
Aceto Corporation |
|
|
Diluted Net Income Per Common Share Excluding
Charges (Non-GAAP Reconciliation) |
|
|
(in thousands, except per share
amounts) |
|
|
|
|
(unaudited) Three Months Ended March 31,
2017 |
|
(unaudited)
Diluted Net Income Per Common Share Three Months Ended
March 31, 2017 |
|
(unaudited) Three Months Ended March 31,
2016 |
|
(unaudited) Diluted
Net Income Per Common Share Three Months Ended March 31,
2016 |
|
(unaudited) Nine Months Ended March 31,
2017 |
|
(unaudited)
Diluted Net Income Per Common Share Nine Months Ended March
31, 2017 |
|
(unaudited) Nine Months Ended March 31,
2016 |
|
(unaudited)
Diluted Net Income Per Common Share Nine Months Ended March
31, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income, as
reported |
|
|
$ |
5,588 |
|
|
$ |
0.16 |
|
|
$ |
10,424 |
|
|
$ |
0.35 |
|
|
|
$ |
9,409 |
|
$ |
0.30 |
|
$ |
27,992 |
|
|
$ |
0.95 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of intangible assets |
|
|
|
8,001 |
|
|
|
0.22 |
|
|
|
2,883 |
|
|
|
0.10 |
|
|
|
|
14,167 |
|
|
0.44 |
|
|
8,325 |
|
|
|
0.29 |
|
Transaction costs related to acquisitions |
|
|
|
(191 |
) |
|
|
(0.01 |
) |
|
|
- |
|
|
|
- |
|
|
|
|
8,818 |
|
|
0.28 |
|
|
- |
|
|
|
- |
|
Separation and relocation costs |
|
|
|
246 |
|
|
|
0.01 |
|
|
|
- |
|
|
|
- |
|
|
|
|
529 |
|
|
0.02 |
|
|
- |
|
|
|
- |
|
Step-up
of inventory |
|
|
|
2,100 |
|
|
|
0.06 |
|
|
|
- |
|
|
|
- |
|
|
|
|
2,266 |
|
|
0.07 |
|
|
- |
|
|
|
- |
|
Contingent consideration |
|
|
|
- |
|
|
|
- |
|
|
|
(1,074 |
) |
|
|
(0.04 |
) |
|
|
|
- |
|
|
- |
|
|
(1,074 |
) |
|
|
(0.04 |
) |
Amortization of debt discount (non-cash interest expense) |
|
|
|
1,263 |
|
|
|
0.04 |
|
|
|
1,184 |
|
|
|
0.04 |
|
|
|
|
3,729 |
|
|
0.12 |
|
|
1,771 |
|
|
|
0.06 |
|
Amortization of debt issuance costs |
|
|
|
208 |
|
|
|
0.01 |
|
|
|
209 |
|
|
|
0.01 |
|
|
|
|
626 |
|
|
0.02 |
|
|
313 |
|
|
|
0.01 |
|
Amortization of deferred financing costs |
|
|
|
300 |
|
|
|
0.01 |
|
|
|
- |
|
|
|
- |
|
|
|
|
300 |
|
|
0.01 |
|
|
- |
|
|
|
- |
|
Termination of interest rate swap |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
- |
|
|
- |
|
|
420 |
|
|
|
0.01 |
|
Environmental remediation charge |
|
|
|
733 |
|
|
|
0.02 |
|
|
|
- |
|
|
|
- |
|
|
|
|
903 |
|
|
0.03 |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted income
excluding charges |
|
|
|
18,248 |
|
|
|
0.52 |
|
|
|
13,626 |
|
|
|
0.46 |
|
|
|
|
40,747 |
|
|
1.29 |
|
|
37,747 |
|
|
|
1.28 |
|
Adjustments to
provision for income taxes |
|
|
|
4,684 |
|
|
|
0.13 |
|
|
|
1,152 |
|
|
|
0.04 |
|
|
|
|
11,642 |
|
|
0.37 |
|
|
3,609 |
|
|
|
0.12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted net income
(Non-GAAP) |
|
|
$ |
13,564 |
|
|
$ |
0.39 |
|
|
$ |
12,474 |
|
|
$ |
0.42 |
|
|
|
$ |
29,105 |
|
$ |
0.92 |
|
$ |
34,138 |
|
|
$ |
1.16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted weighted
average shares outstanding |
|
|
|
35,121 |
|
|
|
35,121 |
|
|
|
29,620 |
|
|
|
29,620 |
|
|
|
|
31,792 |
|
|
31,792 |
|
|
29,536 |
|
|
|
29,536 |
|
|
NOTE: Items identified in the above table are not in
accordance with, or an alternative method for, generally accepted
accounting principles (GAAP) in the United States. These items
should not be reviewed in isolation or considered substitutes of
the Company's financial results as reported in accordance with
GAAP. Due to the nature of these items, it is important to identify
these items and to review them in conjunction with the Company's
financial results reported in accordance with GAAP. The exclusion
of these items also allows investors to compare results of
operations in the current period to prior period’s results based on
the Company’s fundamental business performance and analyze the
operating trends of the business. The exclusion of these items also
allows management to evaluate performance of its business
units. The Company does not provide reconciliations of GAAP
and non-GAAP projections as such projections are intended for
directional purposes only. |
Investor Relations Contact:
LHA
Jody Burfening
jburfening@lhai.com
(212) 838-3777